AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML Presented ByDr Hartmut Döhner, Universitätsklinikum Ulm, Germany TrialPhase 2, AMLSG 16-10 ConferenceASH 2021 4 February, 2022 11:53